Further, the modest effect of Flt3L on i.t T cell activation at this early timepoint, suggests that the impact of Flt3L on DC-mediated tumor Ag cross-presentation may play a key role in preventing late tumor relapses in the combined treatment. This evidence concerns the gene FLT3LG and neoplasm.